Wan Zainira Wan Zain

Wan Zainira Wan Zain

Auto-generated profile, based on publicly available information

Wan Zainira Wan Zain

Department of Surgery, School of Medical Sciences, Universiti Sains Malaysia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2019 in Korean Journal of Family Medicine
Verified
Journal Article
Open access
PDF file
POPoh Siang Ooi
Poh Siang Ooi
NDNANI DRAMAN
NANI DRAMAN
SYSiti Suhaila Mohd Yusoff
Siti Suhaila Mohd Yusoff
WZWan Zainira Wan Zain
Wan Zainira Wan Zain
DGDharmendra Ganasagaran
Dharmendra Ganasagaran
HCHui Heng Chua
Hui Heng Chua
Mammary Paget's disease is clinically defined as skin inflammation of the nipple area and is an adenocarcinoma of the epidermis of the nipple. The pathogenesis of mammary Paget's disease is relatively unknown; nonetheless, there are two popular theories that support the underlying carcinoma and de novo carcinogenesis. For the attending medical practitioner, mammary Paget's disease poses a diagnostic and therapeutic dilemma, especially in the absence of a clinically palpable breast mass. We report a rare case of a 48-year-old Malay woman who presented at Hospital Universiti Sains Malaysia, Kelantan, Malaysia with the symptom of skin erosion on the left nipple and unresponsiveness to multiple topical treatments. A full evaluation and assessment of the patient were conducted, and mammary Paget's disease was diagnosed.

31 December 2022 in Annals of Coloproctology
Verified
Journal Article
Open access
PDF file
NPNelson Rao Pushpanathan
Nelson Rao Pushpanathan
MHMojd Nizam Md Hashim
Mojd Nizam Md Hashim
ZZZalina Zahari
Zalina Zahari
SASyed Hassan Syed Abd. Aziz
Syed Hassan Syed Abd. Aziz
WZWan Zainira Wan Zain
Wan Zainira Wan Zain
Andee Dzulkarnaen ZakariaAndee Dzulkarnaen Zakaria
Andee Dzulkarnaen Zakaria
Purpose: Laparoscopic appendicectomy (LA) has several advantages over conventional open appendicectomy (OA). However, about 5% to 10% of LA patients still need to be converted to open surgery. Identifying risk factors that contribute to conversion to OA allows for early identification of patients who may benefit from primary OA. This study aimed to determine the conversion rate of LA to OA and to identify its associated risk factors among patients with acute or perforated appendicitis.Methods: A retrospective review of medical records was performed among patients with acute or perforated appendicitis who underwent LA between December 2015 and January 2017. With the use of multivariable logistic regression analyses, the predictors of conversion from laparoscopic to OA were investigated.Results: Out of 120 patients, 33 cases were converted to OA which gives a conversion rate of 27.5%. Among 33 patients who were converted to OA, 27 patients (81.8%) had perforated appendix, while in the LA group, perforated appendix cases consisted of 34.5% (P<0.001). Histopathology of the appendix was the predictor of conversion from LA to OA (adjusted odds ratio, 8.82; 95% confidence interval, 3.13–24.91; P<0.001).Conclusion: The result from our study shows that the overall conversion rate for the study period was high. Patients with perforated appendicitis had a higher risk of conversion to OA. Therefore, preoperative diagnosis of perforated appendicitis may be paramount in predicting conversion to OA.

31 December 2020 in Annals of Coloproctology
Verified
Journal Article
Open access
PDF file
SAShahidah Che Alhadi
Shahidah Che Alhadi
WZWan Zainira Wan Zain
Wan Zainira Wan Zain
ZZZalina Zahari
Zalina Zahari
MHMohd Nizam Md Hashim
Mohd Nizam Md Hashim
SASyed Hassan Syed Abd. Aziz
Syed Hassan Syed Abd. Aziz
AZAndee Dzulkarnaen Zakaria
Andee Dzulkarnaen Zakaria
Purpose: Guaiac fecal occult blood test (gFOBT) has been the standard for colorectal screening but it has low sensitivity and specificity. This study evaluated the use of fecal tumor M2-pyruvate kinase (M2-PK) for detection of colorectal cancer and to compare with the current surveillance tool; gFOBT in symptomatic adult subjects underwent colonoscopy.Methods: Stool samples were collected prospectively from symptomatic adults who had elective colonoscopy from September 2014 to January 2016 and were analyzed with the ScheBo M2-PK Quick test and laboratory detection of fecal hemoglobin.Results: The results were correlated to the colonoscopy findings and/or histopathology report. Eighty-five subjects (age of 56.8 ± 15.3 years [mean ± standard deviation]) were recruited with a total of 17 colorectal cancer (20.0%) and 10 colorectal adenoma patients (11.8%). The sensitivity of M2-PK test in colorectal cancer detection was higher than gFOBT (100% vs. 64.7%). M2-PK test had a lower specificity when compared to gFOBT (72.5% vs. 88.2%) in colorectal cancer detection. The positive and negative predictive values were 47.2% and 100% for M2-PK test and 57.9% and 90.9% for gFOBT.Conclusion: Fecal M2-PK Quick test has a high sensitivity for detection of colorectal cancer when compared to gFOBT, making it the potential choice for colorectal tumor screening biomarker in the future.

31 October 2023 in Annals of Coloproctology
Verified
Journal Article
Open access
PDF file
SLSee Liang Lim
See Liang Lim
WZWan Zainira Wan Zain
Wan Zainira Wan Zain
ZZZalina Zahari
Zalina Zahari
Andee Dzulkarnaen ZakariaAndee Dzulkarnaen Zakaria
Andee Dzulkarnaen Zakaria
MHMojd Nizam Md Hashim
Mojd Nizam Md Hashim
ASAhmad Shanwani Mohamed Sidek
Ahmad Shanwani Mohamed Sidek
Purpose: Oncological outcomes following rectal cancer surgery have improved significantly over recent decades with lower recurrences and longer overall survival. However, many of the patients experienced low anterior resection syndrome (LARS). This study identified the prevalence and risk factors associated with the development of LARS.Methods: This cross-sectional study involved patients who were diagnosed with rectal cancer and had undergone sphincter-preserving low anterior resection from January 2011 to December 2020. Upon clinic follow-up, patients were asked to complete an interviewed based questionnaire (LARS score) designed to assess bowel dysfunction after rectal cancer surgery.Results: Out of 76 patients, 25 patients (32.9%) had major LARS, 10 patients (13.2%) had minor LARS, and 41 patients (53.9%) had no LARS. The height of tumor from anal verge showed an association with the development of major LARS (P=0.039). Those patients with less than 8 cm tumor from anal verge had an increased risk of LARS by 3 times compared to those with 8 cm and above (adjusted odds ratio, 3.11; 95% confidence interval, 1.06–9.13).Conclusion: Results from our study show that low tumor height was a significant risk factor that has a negative impact on bowel function after surgery. The high prevalence of LARS emphasizes the need for study regarding risk factors and the importance of understanding the pathophysiology of LARS, in order for us to improve patient bowel function and quality of life after rectal cancer surgery.

11 December 2020 in Oncology Letters
Verified
Journal Article
Open access
PDF file
HRHarishini Rajaratinam
Harishini Rajaratinam
NRNur Syahmina Rasudin
Nur Syahmina Rasudin
TDTengku Ahmad Damitri Al-Astani Tengku Din
Tengku Ahmad Damitri Al-Astani Tengku Din
NMNoor Fatmawati Mokhtar
Noor Fatmawati Mokhtar
MYMaya Mazuwin Yahya
Maya Mazuwin Yahya
WAN EZUMI MOHD FUADWAN EZUMI MOHD FUAD
WAN EZUMI MOHD FUAD
Neonatal Nav1.5 (nNav1.5) is the alternative splice variant of Nav1.5 and it has been widely associated with the progression of breast cancer. The immunological context of nNav1.5 with respect to breast cancer metastases remains unexplored. The presence of antibodies against nNav1.5 may highlight the immunogenicity of nNav1.5. Hence, the aim of the present study was to detect the presence of antineonatal Nav1.5 antibodies (antinNav1.5‑Ab) in the serum of patients with breast cancer and to elucidate the effects of breast cancer therapy on its expression. A total of 32 healthy female volunteers and 64 patients with breast cancer were randomly recruited into the present study as the control and breast cancer group, respectively. Patients with breast cancer were divided equally based on their pre‑ and ongoing‑treatment status. Serum samples were tested with in‑house indirect enzyme‑linked immunosorbent assay (ELISA) to detect antinNav1.5‑Ab, CD25 (T regulatory cell marker) using an ELISA kit and Luminex assay to detect the expression of metastasis‑associated cytokines, such as vascular endothelial growth factor (VEGF), interleukin (IL)‑6, IL‑10, IL‑8, chemokine (C‑C motif) ligand 2 and tumor necrosis factor‑alpha (TNF‑α) The mean difference in the expression of antinNav1.5‑Ab among the three groups (control, pretreatment and ongoing‑treatment) was significant (P=0.0005) and the pretreatment breast cancer group exhibited the highest expression. The concentration of CD25 was highest in the pretreatment breast cancer group compared with the control and ongoing‑treatment groups. There was a significant positive correlation between antinNav1.5‑Ab and IL‑6 in the pretreatment group (r=0.7260; P=0.0210) and a significant negative correlation between antinNav1.5‑Ab and VEGF in the ongoing‑treatment group (r=‑0.842; P‑value=0.0040). The high expression of antinNav1.5‑Ab in the pretreatment group was in accordance with the uninterrupted presence of metastasis and highlighted the immunogenicity of nNav1.5 whereas the low expression of antinNav1.5‑Ab in the ongoing‑treatment group reflected the efficacy of breast cancer therapy in eliminating metastases. The augmented manifestation of T regulatory cells in the pretreatment group highlighted the functional role of nNav1.5 in promoting metastasis. The parallel expression of antinNav1.5‑Ab with the imbalanced expression of cytokines promoting metastasis (IL‑8, IL‑6 and TNF‑α) and cytokines that prevent metastasis (IL‑10) indicated the role of nNav1.5 in breast cancer growth. The expression of antinNav1.5‑Ab in accordance to the metastatic microenvironment indicates the immunogenicity of the protein and highlights the influence of breast cancer therapy on its expression level.

6 October 2025 in Annals of Medicine
Verified
Journal Article
Open access
NZNur Fatihah Mohd Zuhdi
Nur Fatihah Mohd Zuhdi
Alaa SiddigAlaa Siddig
Alaa Siddig
SNSiti Norasikin Mohd Nafi
Siti Norasikin Mohd Nafi
SSSalzihan Md Salleh
Salzihan Md Salleh
MYMaya Mazuwin Yahya
Maya Mazuwin Yahya
wan faiziah wan rahmanwan faiziah wan rahman
wan faiziah wan rahman
Breast cancer is a heterogeneous disease that claims 670,000 lives by 2022. Omic technologies, particularly next generation sequencing (NGS) offers promising avenues for precision medicine. American Society of Clinical Oncology (ASCO) outlines genomic testing's utility, emphasizing prognostic and diagnostic potential. This review succinctly explores NGS's evolution and clinical applications of NGS in breast cancer, thereby guiding future research to enhance patient care. Comprehensive literature searches were conducted using databases such as PubMed, Google Scholar, and ResearchGate, focusing on keywords including breast cancer, HER-2 low breast cancer, circulating tumour DNA, single-cell RNA sequencing, and next-generation sequencing. Peer-reviewed, high-quality articles published in English were selected for inclusion. Previous studies have explored the evolution of NGS technology and its clinical applications in breast cancer, including genomic and transcriptomic characterization, treatment guidance, and resistance prediction. Molecular profiling of challenging entities such as early-onset breast cancer and HER-2 low tumours was summarized, with key findings highlighted. This review also discusses emerging technologies, including circulating DNA and single-cell sequencing, as promising avenues for discovery. NGS has revealed the genomic and transcriptomic diversity of breast cancer, identifying actionable alterations associated with chemotherapy response and resistance to therapies such as trastuzumab, TKIs, and CDK4/6 inhibitors. Circulating tumour DNA (ctDNA) shows potential for diagnosis, prediction, prognosis, and monitoring, despite tumour heterogeneity. Single-cell analysis enables exploration of individual cell transcriptomes, though high costs and low throughput remain barriers to widespread adoption. HER2-low tumours continue to pose significant research challenges.